Flunisolide

Nasal
Perennial allergic rhinitis, Seasonal allergic rhinitis

Patient with active or latent TB infection, untreated bacterial, fungal, or systemic viral infection or ocular herpes simplex; recurrent epistaxis; previous treatment with systemic corticosteroids for prolonged period; on alternate-day prednisone regimens for any disease. Avoid use in patient with recent nasal septal ulcers, nasal trauma or surgery until healing has occurred. Not for use in the presence of untreated localised infection involving the nasal mucosa. Avoid exposure to chickenpox or measles. May mask the signs of infection (including fungal infection). Avoid abrupt withdrawal. Children. Pregnancy and lactation.

Significant: Growth retardation in children; suppression of hypothalamic-pituitary-adrenal (HPA) axis (especially in younger children or in patients receiving chronic high doses), immunosuppression (including increased incidence of secondary infection or prolongation or exacerbation of viral infection), nasal septal perforation, nasal ulceration, epistaxis. Rarely, development of localised Candida albicans infections of the nose and/or pharynx.
Eye disorders: Watery eyes.
Gastrointestinal disorders: Nausea, vomiting, temporary or permanent ageusia.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Transient nasal burning and stinging; nasal congestion, nasal irritation, sneezing, sore throat, temporary or permanent anosmia.

Inhalation/Respiratory/Nasal: C

Monitor growth in paediatric patients (for prolonged treatment), signs and symptoms of HPA axis suppression or adrenal insufficiency, signs of nasal ulceration or septal perforation; candida infection with long term use.

Increase risk of HPA suppression with prednisone.

Description:
Mechanism of Action: Flunisolide is a synthetic fluorinated corticosteroid which decreases inflammation by suppressing the polymorphonuclear leucocytes migration and reversal of increased capillary permeability.
Pharmacokinetics:
Absorption: Absorbed approximately 50%.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 82153, Flunisolide. https://pubchem.ncbi.nlm.nih.gov/compound/Flunisolide. Accessed Sept. 28, 2022.

Store between 15-30°C.

Thuốc kháng histamin & kháng dị ứng

R01AD04 - flunisolide ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.

Anon. Flunisolide (Nasal). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/09/2022.

Buckingham R (ed). Flunisolide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/09/2022.

Flunisolide Solution (Ingenus Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/09/2022.

Flunisolide. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 12/09/2022.